The development of an agent
synthetic opens the way for new
disease therapies
autoimmune
TESTED ON ANIMALS WITH MULTIPLE SCLEROSIS
MADRID, 18 Abr. (IRIN) - Scientists
Scripps Research Institute in Jupiter (USA) have developed a new agent that could provide a new mode of therapy for autoimmune disease.
The researchers, who published their findings in the journal Nature, show a lower severity of disease in an animal model of multiple sclerosis treated with a new synthetic component.
The current study focuses on the suppression of T helper cells known as TH17 cells. These cells have pathological roles in autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.
The authors, led by Thomas Burris, report that the development of a synthetic ligand, SR1001, which is aimed at orphan receptors associated with retinoic acid receptor alpha and gamma, involved in TH17 cell development. SR1001 blocks the development of TH17 cells in culture and is also effective in the inhibition of a mouse model of multiple sclerosis.
The researchers found no obvious adverse effects in animals treated with SR1001. Therefore, SR1001 could represent a new class of drugs for the treatment of autoimmune diseases involving TH17 cells and other disorders involving orphan receptors associated with retinoic acid receptor.
A recent study also published in the journal Nature reported the removal of TH17 cells by targeting RORgamma derivative of the drug digoxin heart.
0 comments:
Post a Comment